Reducing the risk of failure: biomarker-guided trial design

被引：12
|
作者：
Townsend, Michael J. [1 ]
Arron, Joseph R. [2 ]
机构：
[1] Genentech Inc, Biomarker Discovery OMNI, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Immunol Discovery, 1 DNA Way, San Francisco, CA 94080 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 08期
关键词：
D O I：
10.1038/nrd.2016.124
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.
引用
收藏
页码：517 / 518
页数：2
相关论文
共 50 条
  • [21] Biomarker-Guided Development of DNA Repair Inhibitors
    Cleary, James M.
    Aguirre, Andrew J.
    Shapiro, Geoffrey I.
    D'Andrea, Alan D.
    MOLECULAR CELL, 2020, 78 (06) : 1070 - 1085
  • [22] Emerging Biomarker-Guided Therapies in Prostate Cancer
    Deluce, Jasna E.
    Cardenas, Luisa
    Lalani, Aly-Khan
    Vareki, Saman Maleki
    Fernandes, Ricardo
    CURRENT ONCOLOGY, 2022, 29 (07) : 5054 - 5076
  • [23] Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?
    Albert, Christian
    Haase, Michael
    Albert, Annemarie
    Zapf, Antonia
    Braun-Dullaeus, Ruediger Christian
    Haase-Fielitz, Anja
    ANNALS OF LABORATORY MEDICINE, 2021, 41 (01) : 1 - 15
  • [24] Biomarker-guided management of acute kidney injury
    Kane-Gill, Sandra L.
    Meersch, Melaine
    Bell, Max
    CURRENT OPINION IN CRITICAL CARE, 2020, 26 (06) : 556 - 562
  • [25] Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
    Antoniou, Miranta
    Jorgensen, Andrea L.
    Kolamunnage-Dona, Ruwanthi
    PLOS ONE, 2016, 11 (02):
  • [26] A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.
    Lo, Serigne N.
    Gide, Tuba Nur
    Gonzalez, Maria
    Silva, Ines
    Menzies, Alexander M.
    Carlino, Matteo S.
    Scolyer, Richard A.
    Heritier, Stephane
    Wilmott, James S.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials
    Park, Jay J. H.
    Harari, Ofir
    Dron, Louis
    Mills, Edward J.
    Thorlund, Kristian
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [28] Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
    Yoon, Soo-Young
    Kim, Jin-Sug
    Jeong, Kyung-Hwan
    Kim, Su-Kang
    MEDICINA-LITHUANIA, 2022, 58 (03):
  • [29] Biomarker-guided therapy for colorectal cancer: strength in complexity
    Sveen, Anita
    Kopetz, Scott
    Lothe, Ragnhild A.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 11 - 32
  • [30] Limited use of biomarker-guided therapy in mild asthma
    Malinovschi, Andrei
    LANCET RESPIRATORY MEDICINE, 2020, 8 (07): : 648 - 649
12345